{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:05:19Z","timestamp":1786118719607,"version":"build-2736575974"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>The approval of belimumab and anifrolumab has expanded the scope of treatment for systemic lupus erythematosus (SLE) patients. However, many patients remain refractory to currently available therapies and suffer from drug toxicities. This review will discuss approved and target-specific therapeutics in development that bring hope for better SLE treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Since the last review on this subject in the journal, the FDA has approved anifrolumab and belimumab for SLE and lupus nephritis (LN), respectively. A fully humanized anti-CD20, obinutuzumab, met the primary end point in a phase II trial in LN. A Tyk2 inhibitor, deucravacitinib, and an antibody targeting plasmacytoid dendritic cells, litifilimab, met the primary end point in phase II trials in SLE and cutaneous lupus erythematosus (CLE). Ustekinumab and baricitinib met the primary end point in phase II but not in phase III trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>While many drug candidates which met the end points in phase II trials have failed phase III trials, the number of target-specific therapies for SLE has continued to expand.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001003","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T07:04:09Z","timestamp":1706771049000},"page":"169-175","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["Emerging biologic therapies for systemic lupus erythematosus"],"prefix":"10.1097","volume":"36","author":[{"given":"Hiroshi","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michelle","family":"Kahlenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/BOR.0000000000000736","article-title":"Biologic therapies for systemic lupus erythematosus: where are we now?","volume":"32","author":"Murphy","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumab monotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat Med"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.4049\/jimmunol.179.5.3351","article-title":"Depletion of B cells in murine lupus: efficacy and resistance","volume":"179","author":"Ahuja","year":"2007","journal-title":"J Immunol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1002\/art.11354","article-title":"B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations","volume":"48","author":"Stohl","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1074-7613(04)00079-2","article-title":"Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF","volume":"20","author":"Lesley","year":"2004","journal-title":"Immunity"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/14712598.2023.2178297","article-title":"Belimumab for the treatment of pediatric patients with lupus nephritis","volume":"23","author":"Stohl","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2215\/CJN.02520322","article-title":"Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN Study","volume":"17","author":"Furie","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.it.2011.06.004","article-title":"BAFF and selection of autoreactive B cells","volume":"32","author":"Liu","year":"2011","journal-title":"Trends Immunol"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.immuni.2004.05.010","article-title":"Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches","volume":"20","author":"Thien","year":"2004","journal-title":"Immunity"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of belimumab after rituximab in systemic lupus erythematosus: a randomized controlled trial","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann Intern Med"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"e31837","DOI":"10.1371\/journal.pone.0031837","article-title":"Selective APRIL blockade delays systemic lupus erythematosus in mouse","volume":"7","author":"Huard","year":"2012","journal-title":"PLoS One"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1177\/09612033221097812","article-title":"Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: a self-controlled before-after trial","volume":"31","author":"Sun","year":"2022","journal-title":"Lupus"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sjogren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"Dorner","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"CD40-CD40 ligand","volume":"67","author":"van Kooten","year":"2000","journal-title":"J Leukoc Biol"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1172\/JCI118643","article-title":"Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production","volume":"97","author":"Desai-Mehta","year":"1996","journal-title":"J Clin Invest"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev.iy.11.040193.001555","article-title":"T cell-dependent B cell activation","volume":"11","author":"Parker","year":"1993","journal-title":"Annu Rev Immunol"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","article-title":"Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys","volume":"181","author":"Crispin","year":"2008","journal-title":"J Immunol"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"903","DOI":"10.4049\/jimmunol.1700418","article-title":"IL-23 limits the production of IL-2 and promotes autoimmunity in lupus","volume":"199","author":"Dai","year":"2017","journal-title":"J Immunol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.4049\/jimmunol.0903595","article-title":"Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL\/6-lpr\/lpr mice","volume":"184","author":"Kyttaris","year":"2010","journal-title":"J Immunol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4049\/jimmunol.1400931","article-title":"IL-17 promotes murine lupus","volume":"193","author":"Amarilyo","year":"2014","journal-title":"J Immunol"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.41179","article-title":"Maintenance of efficacy and safety of ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","volume":"81","author":"van Vollenhoven","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.4049\/jimmunol.1301859","article-title":"Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus","volume":"192","author":"Kato","year":"2014","journal-title":"J Immunol"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/art.40380","article-title":"Blockade of Treg cell differentiation and function by the interleukin-21-mechanistic target of rapamycin axis via suppression of autophagy in patients with systemic lupus erythematosus","volume":"70","author":"Kato","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/art.34502","article-title":"N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Lai","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13063-023-07083-9","article-title":"Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and its associated complications: a randomized double-blind clinical trial study","volume":"24","author":"Abbasifard","year":"2023","journal-title":"Trials"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1136\/annrheumdis-2022-222335","article-title":"Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus","volume":"81","author":"Dorner","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1535370218824547","article-title":"IL-12 and IL-23\/Th17 axis in systemic lupus erythematosus","volume":"244","author":"Larosa","year":"2019","journal-title":"Exp Biol Med (Maywood)"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","article-title":"Immunopathogenic mechanisms of systemic autoimmune disease","volume":"382","author":"Wahren-Herlenius","year":"2013","journal-title":"Lancet"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/art.39950","article-title":"Gene expression and pharmacodynamic changes in 1,760 systemic lupus erythematosus patients from two phase III trials of BAFF blockade with tabalumab","volume":"69","author":"Hoffman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","article-title":"New insights into the immunopathogenesis of systemic lupus erythematosus","volume":"12","author":"Tsokos","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.immuni.2006.08.010","article-title":"Type I interferon in systemic lupus erythematosus and other autoimmune diseases","volume":"25","author":"Banchereau","year":"2006","journal-title":"Immunity"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0002-9440(10)61689-6","article-title":"Plasmacytoid dendritic cells (natural interferon- alpha\/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions","volume":"159","author":"Farkas","year":"2001","journal-title":"Am J Pathol"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"e20190811","DOI":"10.1084\/jem.20190811","article-title":"Re-evaluation of human BDCA-2+ DC during acute sterile skin inflammation","volume":"217","author":"Chen","year":"2020","journal-title":"J Exp Med"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N Engl J Med"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:32:31Z","timestamp":1786033951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001003","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}